[A17-01] Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) – Benefit assessment according to § 35a Social Code Book V
Last updated 06.07.2017
Project no.:
A17-01
Commission:
Commission awarded on 13.01.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2017-04-18.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A13-09 | Vandetanib (second assessment) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A12-09 | Vandetanib - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A21-127 | Vandetanib (medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period) | Commission completed |
Federal Joint Committee (G-BA)
2017-07-06 A G-BA decision was published.